{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:09:37Z","timestamp":1793376577554,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Study for Monitoring Antimicrobial Resistance Trends (SMART) is an international surveillance program longitudinally monitoring aerobic and facultative Gram-negative bacteria (GNB) involvement in infections and their antimicrobial resistance profiles. Here the incidence and resistance patterns of Chinese GNB isolates from bloodstream infections (BSI), intraabdominal infections (IAI), respiratory tract infections (RTI) and urinary tract infections (UTI) to commonly used antibacterial agents has been updated. 4,975 GNB isolates collected from 22 hospitals across 7 regions of China from 2019 to 2020 were analyzed. Antimicrobial minimum inhibitory concentrations were assessed using broth microdilution, and susceptibility interpretations followed the breakpoints of European Committee on Antimicrobial Susceptibility Testing 2022 or Clinical and Laboratory Standards Institute.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study affirmed that <jats:italic>Escherichia coli<\/jats:italic> (Ec) was the most commonly identified GNB (32.1%) and then <jats:italic>Klebsiella pneumoniae<\/jats:italic> (Kp) (25.3%), <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (Pa) (13.9%) and <jats:italic>Acinetobacter baumannii<\/jats:italic> (10.5%). The detection rates of carbapenem-resistant (CR) Enterobacterales varied across major infection sites, ranging from 10.3% in UTI to 18.9% in RTI. Specifically, the detection rates of CR-Kp and CR-Pa ranged from 16.2% in IAI to 35.8% in UTI and from 16.1% in UTI to 38.0% in RTI, respectively. Extended-spectrum \u03b2-lactamases (ESBL)-producing Ec and Kp bacteria exhibited over 91.7% susceptibility to carbapenems and at least 87.8% susceptibility to amikacin and colistin, but showed lower susceptibility to piperacillin\/tazobactam (57.5\u201386.2%), levofloxacin (10.8\u201339.7%) and aztreonam (15.3\u201327.6%) across different infection sources. Amikacin showed higher efficacy against CR strains compared to other commonly used antibacterial drugs, with 80.0% susceptibility against CR-Ec and 82.3% susceptibility against CR-Pa, while only 36.3% susceptibility was observed against CR-Kp.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study found varying incidences of CR isolates in Chinese hospitals. Treatment options remained limited due to resistance to multiple antibacterial agents. Carbapenems demonstrated effective antimicrobial in vitro activity against ESBL-producing Enterobacterales found in BSI, IAI, UTI and RTI, outperforming broad-spectrum cephalosporins and other \u03b2-lactamase inhibitors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12866-024-03526-8","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T02:09:26Z","timestamp":1734574166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Susceptibility of various Gram-negative bacteria to antibacterial agents: SMART in China 2019\u20132020"],"prefix":"10.1186","volume":"24","author":[{"given":"Ying","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"3526_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"3526_CR2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132013;2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9.","journal-title":"Lancet"},{"key":"3526_CR3","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","volume":"400","author":"KS Ikuta","year":"2022","unstructured":"Ikuta KS, Swetschinski LR, Robles Aguilar G, Sharara F, Mestrovic T, Gray AP, et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2022;400:2221\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(22)02185-7.","journal-title":"Lancet"},{"key":"3526_CR4","unstructured":"WHO. Global Antimicrobial Resistance Surveillance System (GLASS). 2015. Available at: https:\/\/www.who.int\/initiatives\/glass. Accessed 31 May 2024."},{"key":"3526_CR5","unstructured":"WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed, https:\/\/www.who.int\/en\/news-room\/detail\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed, 2017 Accessed 31 May 2024."},{"key":"3526_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/molecules25061340","volume":"25","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules. 2020;25:25. https:\/\/doi.org\/10.3390\/molecules25061340.","journal-title":"Molecules."},{"key":"3526_CR7","doi-asserted-by":"publisher","first-page":"Fso339","DOI":"10.4155\/fsoa-2018-0071","volume":"4","author":"MV Villegas","year":"2018","unstructured":"Villegas MV, Lyon S. Gram-negative infections: evolving treatments with expanding options. Future Sci OA. 2018;4:Fso339. https:\/\/doi.org\/10.4155\/fsoa-2018-0071.","journal-title":"Future Sci OA"},{"key":"3526_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/pathogens10101310","volume":"10","author":"G Mancuso","year":"2021","unstructured":"Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021;10:1310. https:\/\/doi.org\/10.3390\/pathogens10101310.","journal-title":"Pathogens"},{"key":"3526_CR9","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1128\/aac.00296-11","volume":"55","author":"KM Papp-Wallace","year":"2011","unstructured":"Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943\u201360. https:\/\/doi.org\/10.1128\/aac.00296-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"3526_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11908-020-0716-3","volume":"22","author":"MJ Lasko","year":"2020","unstructured":"Lasko MJ, Nicolau DP. Carbapenem-resistant enterobacterales: considerations for treatment in the era of new antimicrobials and evolving enzymology. Curr Infect Dis Rep. 2020;22:6. https:\/\/doi.org\/10.1007\/s11908-020-0716-3.","journal-title":"Curr Infect Dis Rep"},{"key":"3526_CR11","doi-asserted-by":"publisher","first-page":"e27094","DOI":"10.7759\/cureus.27094","volume":"14","author":"M Al Khamis","year":"2022","unstructured":"Al Khamis M, AlMusa Z, Hashhoush M, Alsaif N, Salam A, Atta M. Carbapenem-resistant Enterobacteriaceae: a retrospective review of presentation, treatment, and clinical outcomes in a tertiary care referral hospital. Cureus. 2022;14:e27094. https:\/\/doi.org\/10.7759\/cureus.27094.","journal-title":"Cureus"},{"key":"3526_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/jpids\/piaa056","volume":"10","author":"JA Karlowsky","year":"2021","unstructured":"Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem\/relebactam against gram-negative bacilli from pediatric patients-study for monitoring antimicrobial resistance trends (SMART) global surveillance program 2015\u20132017. J Pediatr Infect Dis Soc. 2021;10:274\u201381. https:\/\/doi.org\/10.1093\/jpids\/piaa056.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"3526_CR13","first-page":"145","volume":"32","author":"R Cant\u00f3n","year":"2019","unstructured":"Cant\u00f3n R, Loza E, Aznar J, Castillo FJ, Cercenado E, Fraile-Ribot PA, et al. Monitoring the antimicrobial susceptibility of gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017). Rev Esp Quimioter. 2019;32:145\u201355.","journal-title":"Rev Esp Quimioter"},{"key":"3526_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2017.02.018","volume":"88","author":"SH Lob","year":"2017","unstructured":"Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, et al. In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - results from the SMART global surveillance program. Diagn Microbiol Infect Dis. 2017;88:171\u20136. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.02.018.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3526_CR15","unstructured":"Clinical and Laboratory Standards Institute. M100\u2014performance standards for antimicrobial susceptibility testing, 32nd edition. 2023. https:\/\/clsi.org\/media\/wi0pmpke\/m100ed32_sample.pdf. Accessed 25 Sep 2023."},{"key":"3526_CR16","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints - bacteria (v 12.0) - file for screen (1 Jan \u2013\u200931 Dec, 2022). https:\/\/www.eucast.org\/ast_of_bacteria\/previous_versions_of_documents. Accessed on 11 Apr 2024."},{"key":"3526_CR17","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","volume":"67","author":"SS Kadri","year":"2018","unstructured":"Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67:1803\u201314. https:\/\/doi.org\/10.1093\/cid\/ciy378.","journal-title":"Clin Infect Dis"},{"key":"3526_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/antibiotics9040196","volume":"9","author":"S Morris","year":"2020","unstructured":"Morris S, Cerceo E. Trends, epidemiology, and management of multi-drug resistant gram-negative bacterial infections in the hospitalized setting. Antibiot (Basel). 2020;9:9. https:\/\/doi.org\/10.3390\/antibiotics9040196.","journal-title":"Antibiot (Basel)"},{"key":"3526_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4103\/0974-777x.68531","volume":"2","author":"D Rawat","year":"2010","unstructured":"Rawat D, Nair D. Extended-spectrum \u03b2-lactamases in gram negative bacteria. J Glob Infect Dis. 2010;2:263\u201374. https:\/\/doi.org\/10.4103\/0974-777x.68531.","journal-title":"J Glob Infect Dis"},{"key":"3526_CR20","doi-asserted-by":"publisher","unstructured":"Caliskan-Aydogan O, Alocilja EC. A review of carbapenem resistance in Enterobacterales and its detection techniques. Microorganisms. 2023;11. https:\/\/doi.org\/10.3390\/microorganisms11061491.","DOI":"10.3390\/microorganisms11061491"},{"key":"3526_CR21","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s10096-018-3274-y","volume":"37","author":"SH Lob","year":"2018","unstructured":"Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of ertapenem against Enterobacteriaceae in seven global regions-SMART 2012\u20132016. Eur J Clin Microbiol Infect Dis. 2018;37:1481\u20139. https:\/\/doi.org\/10.1007\/s10096-018-3274-y.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3526_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.955774","volume":"12","author":"A Siriphap","year":"2022","unstructured":"Siriphap A, Kitti T, Khuekankaew A, Boonlao C, Thephinlap C, Thepmalee C, et al. High prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates: a 5-year retrospective study at a tertiary hospital in Northern Thailand. Front Cell Infect Microbiol. 2022;12: 955774. https:\/\/doi.org\/10.3389\/fcimb.2022.955774.","journal-title":"Front Cell Infect Microbiol"},{"key":"3526_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/cid\/ciw283","volume":"63","author":"S Karanika","year":"2016","unstructured":"Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and meta-analysis. Clin Infect Dis. 2016;63:310\u20138. https:\/\/doi.org\/10.1093\/cid\/ciw283.","journal-title":"Clin Infect Dis"},{"key":"3526_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12879-020-4889-z","volume":"20","author":"EH Baek","year":"2020","unstructured":"Baek EH, Kim SE, Kim S, Lee S, Cho OH, et al. In Hong S, Successful control of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae ST307 outbreak in a neonatal intensive care unit. BMC Infect Dis. 2020;20:166. https:\/\/doi.org\/10.1186\/s12879-020-4889-z.","journal-title":"BMC Infect Dis"},{"key":"3526_CR25","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1017\/s0950268820003015","volume":"149","author":"P Vachvanichsanong","year":"2020","unstructured":"Vachvanichsanong P, McNeil EB, Dissaneewate P. Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections. Epidemiol Infect. 2020;149:e12. https:\/\/doi.org\/10.1017\/s0950268820003015.","journal-title":"Epidemiol Infect"},{"key":"3526_CR26","first-page":"1097","volume":"98","author":"P Boontham","year":"2015","unstructured":"Boontham P, Soontomrak R. Intra-abdominal infections: prevalence and risk factors of ESBLs infections. J Med Assoc Thai. 2015;98:1097\u2013103.","journal-title":"J Med Assoc Thai"},{"key":"3526_CR27","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1185\/03007991003769068","volume":"26","author":"B Hu","year":"2010","unstructured":"Hu B, Ye H, Xu Y, Ni Y, Hu Y, Yu Y, et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China. Curr Med Res Opin. 2010;26:1443\u20139. https:\/\/doi.org\/10.1185\/03007991003769068.","journal-title":"Curr Med Res Opin"},{"key":"3526_CR28","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/cid\/cit500","volume":"57","author":"MY Lin","year":"2013","unstructured":"Lin MY, Lyles-Banks RD, Lolans K, Hines DW, Spear JB, Petrak R, et al. The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57:1246\u201352. https:\/\/doi.org\/10.1093\/cid\/cit500.","journal-title":"Clin Infect Dis"},{"key":"3526_CR29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1086\/677157","volume":"35","author":"JT Thaden","year":"2014","unstructured":"Thaden JT, Lewis SS, Hazen KC, Huslage K, Fowler VG Jr, Moehring RW, et al. Rising rates of carbapenem-resistant Enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol. 2014;35:978\u201383. https:\/\/doi.org\/10.1086\/677157.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"3526_CR30","first-page":"981","volume":"38","author":"FD Pien","year":"1981","unstructured":"Pien FD, Ho PW. Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate. Am J Hosp Pharm. 1981;38:981\u20139.","journal-title":"Am J Hosp Pharm"},{"key":"3526_CR31","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1017\/s0950268821001254","volume":"149","author":"Q Chen","year":"2021","unstructured":"Chen Q, Li D, Beiersmann C, Neuhann F, Moazen B, Lu G, et al. Risk factors for antibiotic resistance development in healthcare settings in China: a systematic review. Epidemiol Infect. 2021;149:e141. https:\/\/doi.org\/10.1017\/s0950268821001254.","journal-title":"Epidemiol Infect"},{"key":"3526_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv050","volume":"2","author":"HJ Morrill","year":"2015","unstructured":"Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis. 2015;2: ofv050. https:\/\/doi.org\/10.1093\/ofid\/ofv050.","journal-title":"Open Forum Infect Dis"},{"key":"3526_CR33","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dku168","volume":"69","author":"M Paul","year":"2014","unstructured":"Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69:2305\u20139. https:\/\/doi.org\/10.1093\/jac\/dku168.","journal-title":"J Antimicrob Chemother"},{"key":"3526_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1249030","volume":"10","author":"AT Aslan","year":"2023","unstructured":"Aslan AT, Ezure Y, Horcajada JP, Harris PNA, Paterson DL. In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review. Front Med (Lausanne). 2023;10: 1249030. https:\/\/doi.org\/10.3389\/fmed.2023.1249030.","journal-title":"Front Med (Lausanne)"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-024-03526-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-024-03526-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-024-03526-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T03:02:05Z","timestamp":1734577325000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-024-03526-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3526"],"URL":"https:\/\/doi.org\/10.1186\/s12866-024-03526-8","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, approved the study protocol (Approval No: 20210811-33) and agreed to waive patient informed consent due to the retrospective nature of the study and because the specimens were obtained from previous treatments and diagnoses for patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Pengcheng Li is an employee of MSD China. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"524"}}